Compare CYTK & LAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | LAD |
|---|---|---|
| Founded | 1997 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.2B |
| IPO Year | 2004 | 1996 |
| Metric | CYTK | LAD |
|---|---|---|
| Price | $65.16 | $342.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $84.81 | ★ $386.17 |
| AVG Volume (30 Days) | ★ 2.2M | 190.5K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 0.65% |
| EPS Growth | N/A | ★ 18.36 |
| EPS | N/A | ★ 34.59 |
| Revenue | $87,211,000.00 | ★ $37,610,600,000.00 |
| Revenue This Year | $339.72 | $5.55 |
| Revenue Next Year | $79.08 | $4.46 |
| P/E Ratio | ★ N/A | $9.75 |
| Revenue Growth | ★ 2609.26 | 8.42 |
| 52 Week Low | $29.31 | $262.10 |
| 52 Week High | $70.98 | $405.14 |
| Indicator | CYTK | LAD |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 58.38 |
| Support Level | $61.10 | $322.87 |
| Resistance Level | $65.35 | $337.69 |
| Average True Range (ATR) | 3.00 | 8.40 |
| MACD | 0.09 | -0.11 |
| Stochastic Oscillator | 81.20 | 92.96 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Lithia Motors is a retailer of new and used vehicles and related services. The company offers over 50 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2024 was $36.2 billion and we see over $50 billion possible in a few years. The US was 78% of 2024 revenue and the UK second at 19%, due to the 2024 Pendragon acquisition. In 2024, new vehicle sales were about 49% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.